Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: Results of a multicenter, placebo-controlled, randomized trial

Circulation

Volumn 98, Issue 13, 1998, Pages 1268-1278

  Kereiakes, Dean J ^a,b,f   Kleiman, Neal S ^c   Ferguson, James J ^d   Masud, A R Zaki ^e   Broderick, Thomas M ^f   Abbottsmith, Charles W ^f   Runyon, John Paul ^b,f   Anderson, Linda C ^a   Anders, Robert J ^g   Dreiling, Roger J ^g   Hantsbarger, Gary L ^g   Bryzinski, Brian ^g   Topol, Eric J ^h  

^a The Carl & Edyth Lindner Center for Research & Education   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e MILLARD FILLMORE HOSPITAL   (United States)

^f Ohio Heart and Vascular Center   (United States)

^g PFIZER INC   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Glycoproteins; Platelets; Receptors; Thrombosis; Xemilofiban

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; COLLAGEN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PLACEBO; TICLOPIDINE; XEMILOFIBAN;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; FEMALE; HEART MUSCLE REVASCULARIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STENT; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

EID: 0032578441     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.13.1268     Document Type: Article

References (17)

1. The EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockade in low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-1696.
2. Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navettafi FI, Smith JE, Worley SJ, Miller JA, Joseph DM, Sigmon KN, Kitt MM, du Mee CP, Califf RM, Topol EJ. Multicenter, randomized, double-blind placebo controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker integrilin in elective coronary intervention. Circulation. 1995;91:2151-2157.
3. Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, Califf RM, Navetta FI, Willerson JT, Chandra NC, Guerci AD, Ferguson JJ, Harrington RA, Lincoff AM, Yakubov SJ, Bray PF, Bahr RD, Wolfe CL, Yak PG, Anderson HV, Nygaard TW, Mason SJ, Effron MB, Fatterpacker A, Raskin S, Smith J, Brashears L, Gottdiener P, du Mee CP, Kitt MM, Gerstenblith G. Effects of integrilin, a platelet glycoprotein IIb/IIIa antagonist in unstable angina: a randomized multicenter trial. Circulation. 1996;94:2083-2089.
4. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing angioplasty. Circulation. 1997;96:1445-1453.
5. White HD. Platelet Receptor Inhibition for Ischemic Syndrome Management (PRISM): results from late breaking clinical trials sessions at ACC '97. J Am Coll Cardiol. 1997;30:1-7.
6. Antiplatelet Trialist Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
7. Gent M. A systematic overview of randomized trials of antiplatelet agents for the prevention of stroke, myocardial infarction and vascular death. In: Hass WK, Easton JD, eds. Ticlopidine, Platelets and Vascular Disease. New York, NY: Springer Verlag; 1993;99-116.
8. CAPRIE Steering Committee. A randomized, blinded, trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE). Lancet. 1996;348:1329-1339.
9. Phillips DR, Charro IF, Parise LV, Fitzgerald IA. The platelet membrane glycoprotein IIb/IIIa complex. Blood. 1988;71:831-843.
10. Kereiakes DJ, Kleiman N, Ferguson JJ, Runyon JP, Broderick TM, Higby NA, Martin LH, Hantsbarger G, McDonald S, Anders RJ. Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients following coronary stent deployment. Circulation. 1997;96: 1117-1121.
11. Simpfendorfer C, Kottke-Marchant K, Lowrie M, Anders RJ, Burns DM, Miller DP, Cove CS, DeFranco AC, Ellis SG, Molitemo DJ, Raymond RE, Sutton JM, Topol EJ. First chronic platelet glycoprotein IIb/IIIa integrin blockade: a randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions. Circulation. 1997;96:76-81.
12. Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, Feldman R, Palmeri ST, Ault K, Hamilton SA, Rothman JM, Novotny WF, Braunwald E, for the TIMI 12 investigators. A randomized trial of an oral glycoprotein IIb/IIIa antagonist, sibrafiban, in patients post and acute coronary syndrome: results of the TIMI 12 trial. Circulation. 1998;97:340-349.
13. Kereiakes DJ, Runyon JP, Kleiman NS, Higby NA, Anderson LC, Hantsbarger G, McDonald S, Anders RJ. Differential dose response to oral xemilofiban after antecedent intravenous abciximab administration for complex coronary intervention. Circulation. 1996;94:906-910.
14. Practice strategies for elective red blood cell transfusion. Ann Intern Med. 1992;116:403-406.
15. Oliver S, Karim A, Burns DM, Anders RJ. Effect of aspirin on Orbofiban tolerability and pharmacodynamics. Abstracts; XIII World Congress of Cardiology, Rio de Janeiro, Brazil, April 26-30, 1998.
16. PARAGON Investigators. A randomized trial of potent platelet IIb/IIIa antagonism, heparin or both in patients with unstable angina: the PARAGON Study. Circulation. 1996;94(suppl I):I-553. Abstract.
17. Harrington RA, Moliterno DJ, van de Werf K, Keech A, Kleiman N, Bhapkar M, Rames A, Peek M, Topol EJ, Califf RM, Armstrong PW. Delaying and preventing ischemic events in patients with acute coronary syndromes using the platelet glycoprotein IIb/IIIa inhibitor lamifiban. J Am Coll Cardiol. 1997;29:409A. Abstract.